From Oncolysis to Adaptive Immunity: Yellow Fever Virus 17D and Ruxolitinib Activate Antitumor Immune Responses in Pancreatic Cancer Models. (PubMed, Biomedicines) - Aug 28, 2026 - "No systemic cytokine surge, neurovirulence, or viral dissemination was observed, suggesting the safety of the proposed regimen. These findings clarify the immune mechanisms determining the efficacy of YFV 17D combined with ruxolitinib and establish the basis for personalized patient stratification by tumor interferon signaling status."
IO biomarker • Journal • Preclinical • Infectious Disease • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD4 • CD8 • IL12A • KRAS • TP53
|
|
Alina S Nazarenko; Aydar A Ishmukhametov; Ekaterina A Orlova; Grigory A Demyashkin; Grigory L Kozhemyakin; Ilya V Gordeychuk; Kirill N Trachuk; Nadezhda M Kolyasnikova; Vitalii A Kapranov; Yulia K Biryukova
|